Vogenx (VOGX) Q3 2026 earnings summary

Executive summary

• Clinical-stage pipeline centers on mizagliflozin for post-bariatric hypoglycemia (PBH) and gastroparesis, plus GIP-dependent Cushing's syndrome; no product-sales revenue to date.

• August IPO generated $84.4M net proceeds; cash, cash equivalents and marketable securities totaled $82.1M at September 30, 2026.

• EMERGE, a Phase 2b mizagliflozin study for PBH, began in October 2026.

Financial highlights

• Q3 2026 net loss was $4.91M vs. $284K in Q3 2025; 9M net loss was $5.77M vs. $936K.

• Q3 operating expenses were $1.78M vs. $302K YoY; 9M expenses were $2.60M vs. $985K.

• Q3 and 9M results included a $3.44M non-cash warrant fair-value loss; 9M also included a $78K notes fair-value loss and $339K interest income.

• Q3 R&D was $1.08M vs. $125K YoY; G&A was $704K vs. $178K, reflecting higher staffing and public-company costs.

• 9M cash used in operations was $2.92M; investing cash outflow was $76.99M, primarily Treasury purchases, and financing cash inflow was $84.43M from the IPO.

Outlook and guidance

• EMERGE tests mizagliflozin 5 mg and 10 mg for 28 days in ~36 adults with PBH; topline results are expected in H2 2027.

• A Phase 2 study of mizagliflozin for gastroparesis is planned to start in H1 2027.

• Expenses and operating losses are expected to rise as development advances across mizagliflozin programs, VGX-2857 and future candidates, alongside public-company costs.

• Cash resources are expected to fund operations through 2028; substantial additional capital will be needed before any Phase 3 trial, with timing dependent on operating-plan assumptions.

• Future funding may include equity, debt, collaborations or licensing; unavailable or unfavorable financing could delay, reduce or end development programs.